Dengue Fever Vaccines: Progress and Challenges
Alan L. Rothmana, Heather Fribergb
- a1Institute for Immunology and Informatics, Department of Cell and Molecular Biology, University of Rhode Island, Kingston, Rhode Island, USA; email: alan_rothman@uri.edu
- b2Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA; email: heather.l.friberg-robertson.civ@health.mil
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Development of vaccines against dengue has been designated a priority for over 75 years. The completion of Phase III trials and licensing of multiple dengue vaccines have been significant accomplishments of the last 15 years. Despite that progress, a vaccine suitable for broad use has not yet been identified. The scientific challenges of multiple dengue viral serotypes, immune imprinting from previous infections, and immune enhancement of infection and disease remain formidable obstacles to this goal. Further investments in clinical research of natural dengue virus infections and participants in dengue vaccine trials will be needed to enable the development and testing of the next generation of dengue vaccines.
TL;DRInvestments in clinical research of natural dengue virus infections and participants in dengue vaccine trials will be needed to enable the development and testing of the next generation of dengue vaccines. (Semantic Scholar)